Developer docs
API playgroundTry for free, no card

Search company profiles

GlycoVaxyn

Full company profile

uuid000iov1

Namestring
GlycoVaxyn
Legal namestring
Glycovaxyn
Websiteurl
glycovaxyn.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

GlycoVaxyn is a Swiss clinical-stage biotechnology company founded in 2004 and headquartered in Schlieren, Switzerland. According to its firmographic profile, the company develops and manufactures biological conjugate vaccines against bacterial infections using recombinant DNA technology — a glyco-conjugation approach that uses biological (rather than purely chemical) methods to attach polysaccharide antigens to carrier proteins. With 11–50 employees and a private, for-profit corporate structure, GlycoVaxyn operates as a focused specialty biotech targeting bacterial pathogens through its proprietary conjugation platform.

The company's commercial activity to date is centered on R&D pipeline advancement funded by venture capital. Between 2006 and 2010, GlycoVaxyn closed four disclosed financing rounds totaling approximately $34.3 million, with a syndicate of specialist European life-sciences investors — Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity — providing continuity across rounds. Leadership is anchored by Philippe Dro as Chief Executive Officer and board member. No product approvals, commercial launches, named pharmaceutical partners, licensing deals, or revenue figures are disclosed in the available input data, indicating the business remains in a pre-commercial development stage within the disclosed window.

Note on data integrity: the publicly accessible web property at glycovaxyn.com presents generic technology-infrastructure marketing content (server architectures, neural networks, cybersecurity services) with testimonial names drawn from fictional film characters (Sarah Connor, Marcus Wright, Miles Dyson, John Anderson) and self-reported statistics of zero projects, partners, and awards. This content is inconsistent with the firmographic vaccine-biotech profile and is not relied upon as evidence of GlycoVaxyn's products, technology, or customers.

Short descriptiontext

GlycoVaxyn is a privately held, clinical-stage Swiss biotechnology company (founded 2004, Schlieren) that develops recombinant-DNA-based glycoconjugate vaccines against bacterial infections, funded through 2010 by Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bacterial infection vaccines, biological conjugation technology, recombinant DNA vaccines, vaccine development and manufacturing, biopharmaceutical R&D
Industry2 codes
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Infrastructure Services
TypeSubscription Recurring
Description

Providing enterprise technology infrastructure solutions including server architectures, neural network deployments, and cybersecurity services. Revenue appears to be generated through project-based engagements and ongoing service contracts for infrastructure management.

glycovaxyn.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. Its core activity is vaccine research, development, and biological manufacturing of glycoconjugate candidates designed to prevent bacterial disease. The company operates as a small, private Swiss biopharmaceutical firm advancing its proprietary bioconjugate vaccine platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 99.99% uptime for server infrastructure
+1 more record
Product overview1 text field

GlycoVaxyn operates as a technology infrastructure company offering an integrated suite of services centered around Future Infrastructure, Neural Networks, Hardware Integration, and Cyber Security. The core offering combines advanced server architectures (Future Infrastructure) with AI-powered neural network solutions, custom hardware integration for IoT endpoints, and military-grade cybersecurity protection. These services are engineered for scalability and performance, targeting enterprise clients seeking comprehensive digital transformation solutions.

Product and service1 record
1Biological conjugation vaccines for bacterial infections
CategoryBiological conjugation vaccines
Description

Vaccines developed and manufactured using biological conjugation and recombinant DNA technology to prevent bacterial infections. Targeted at public health agencies, global health organizations, and pharmaceutical partners seeking in-licensed or co-developed vaccine candidates.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recombinant vaccine platform company using protein subunit / recombinant DNA technology. Compares on platform-based approach to infectious disease vaccination and capital-intensive development profile.

TypeEmerging player
Description

Smaller-scale vaccine platform company with pipeline targeting infectious disease. Comparable as a peer-stage clinical biotech focused on specialty vaccine indications.

TypeBroad incumbent
Description

Major global vaccine manufacturer with deep portfolio in bacterial and conjugate vaccines. Adjacent incumbent that has historically partnered with and acquired specialty vaccine biotechs of comparable size and platform type.

TypeDirect peer
Description

European vaccine developer with platforms spanning viral and bacterial indications. Compares on European origin, biodefense and infectious disease focus, and clinical-stage specialty vaccine positioning.

TypeDirect peer
Description

Specialty vaccine biotech developing products against bacterial and emerging infectious threats. Comparable on niche infectious disease focus, smaller scale relative to big pharma, and platform-based pipeline approach.

6Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccines division of Sanofi and one of the largest vaccine manufacturers. Broad incumbent with overlapping bacterial and conjugate vaccine programs; comparable as a potential partner/competitor in the same product class.

TypeDirect peer
Description

Vaccine technology company with proprietary adjuvant and recombinant vaccine platforms. Matches on platform-based vaccine development and target markets in infectious disease prevention.

8Valneva
TypeDirect peer
Description

European commercial-stage vaccine biotech that developed bacterial/viral travel vaccines and infectious disease products. Comparable to GlycoVaxyn in geographic roots (Switzerland/France), specialty vaccine focus, and historical Series B/C-stage profile.

9Biological E
TypeEmerging player
Description

Indian vaccine manufacturer with expansive pipeline including conjugate vaccines. Compares in product category (conjugate/bacterial vaccines), though larger scale and geographic focus differ.

TypeBroad incumbent
Description

Leading pharmaceutical company with substantial infectious disease and bacterial vaccine franchises. Represents the scale boundary and potential acquirer profile of a successful smaller biotech platform player.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GlycoVaxyn

Biopharmaceutical vaccinesglycovaxyn.com

GlycoVaxyn is a privately held, clinical-stage Swiss biotechnology company (founded 2004, Schlieren) that develops recombinant-DNA-based glycoconjugate vaccines against bacterial infections, funded through 2010 by Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity.

What GlycoVaxyn does

GlycoVaxyn is a Swiss clinical-stage biotechnology company founded in 2004 and headquartered in Schlieren, Switzerland. According to its firmographic profile, the company develops and manufactures biological conjugate vaccines against bacterial infections using recombinant DNA technology — a glyco-conjugation approach that uses biological (rather than purely chemical) methods to attach polysaccharide antigens to carrier proteins. With 11–50 employees and a private, for-profit corporate structure, GlycoVaxyn operates as a focused specialty biotech targeting bacterial pathogens through its proprietary conjugation platform.

The company's commercial activity to date is centered on R&D pipeline advancement funded by venture capital. Between 2006 and 2010, GlycoVaxyn closed four disclosed financing rounds totaling approximately $34.3 million, with a syndicate of specialist European life-sciences investors — Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity — providing continuity across rounds. Leadership is anchored by Philippe Dro as Chief Executive Officer and board member. No product approvals, commercial launches, named pharmaceutical partners, licensing deals, or revenue figures are disclosed in the available input data, indicating the business remains in a pre-commercial development stage within the disclosed window.

Note on data integrity: the publicly accessible web property at glycovaxyn.com presents generic technology-infrastructure marketing content (server architectures, neural networks, cybersecurity services) with testimonial names drawn from fictional film characters (Sarah Connor, Marcus Wright, Miles Dyson, John Anderson) and self-reported statistics of zero projects, partners, and awards. This content is inconsistent with the firmographic vaccine-biotech profile and is not relied upon as evidence of GlycoVaxyn's products, technology, or customers.

GlycoVaxyn firmographics

Firmographics
Name
GlycoVaxyn
Legal name
Glycovaxyn
Website
https://glycovaxyn.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
GlycoVaxyn is a privately held, clinical-stage Swiss biotechnology company (founded 2004, Schlieren) that develops recombinant-DNA-based glycoconjugate vaccines against bacterial infections, funded through 2010 by Index Ventures, Sofinnova Partners, and Edmond de Rothschild Private Equity.
Ownership category
akta.pro rank

GlycoVaxyn industry classification

Industry
Product category
Biopharmaceutical vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines

Keywords

  • Bacterial infection vaccines
  • Biological conjugation technology
  • Recombinant DNA vaccines
  • Vaccine development and manufacturing
  • Biopharmaceutical R&D

Where GlycoVaxyn is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Markets served

GlycoVaxyn business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Technology Infrastructure Services: Providing enterprise technology infrastructure solutions including server architectures, neural network deployments, and cybersecurity services. Revenue appears to be generated through project-based engagements and ongoing service contracts for infrastructure management.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

GlycoVaxyn product offering

Product offering

Core offering

GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. Its core activity is vaccine research, development, and biological manufacturing of glycoconjugate candidates designed to prevent bacterial disease. The company operates as a small, private Swiss biopharmaceutical firm advancing its proprietary bioconjugate vaccine platform.

Product overview

GlycoVaxyn operates as a technology infrastructure company offering an integrated suite of services centered around Future Infrastructure, Neural Networks, Hardware Integration, and Cyber Security. The core offering combines advanced server architectures (Future Infrastructure) with AI-powered neural network solutions, custom hardware integration for IoT endpoints, and military-grade cybersecurity protection. These services are engineered for scalability and performance, targeting enterprise clients seeking comprehensive digital transformation solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biological conjugation vaccines for bacterial infections Vaccines developed and manufactured using biological conjugation and recombinant DNA technology to prevent bacterial infections. Targeted at public health agencies, global health organizations, and pharmaceutical partners seeking in-licensed or co-developed vaccine candidates.

Quantifiable outcome

  • 99.99% uptime for server infrastructure
  • +1 more outcomes

Companies that use GlycoVaxyn

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

GlycoVaxyn technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

GlycoVaxyn partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights2 records

GlycoVaxyn competitors and assessment

Company assessment

Direct peers

  • Novavax: Recombinant vaccine platform company using protein subunit / recombinant DNA technology. Compares on platform-based approach to infectious disease vaccination and capital-intensive development profile.
  • Bavarian Nordic: European vaccine developer with platforms spanning viral and bacterial indications. Compares on European origin, biodefense and infectious disease focus, and clinical-stage specialty vaccine positioning.
  • Emergent BioSolutions: Specialty vaccine biotech developing products against bacterial and emerging infectious threats. Comparable on niche infectious disease focus, smaller scale relative to big pharma, and platform-based pipeline approach.
  • Dynavax Technologies: Vaccine technology company with proprietary adjuvant and recombinant vaccine platforms. Matches on platform-based vaccine development and target markets in infectious disease prevention.
  • Valneva: European commercial-stage vaccine biotech that developed bacterial/viral travel vaccines and infectious disease products. Comparable to GlycoVaxyn in geographic roots (Switzerland/France), specialty vaccine focus, and historical Series B/C-stage profile.

Emerging players

  • VBI Vaccines: Smaller-scale vaccine platform company with pipeline targeting infectious disease. Comparable as a peer-stage clinical biotech focused on specialty vaccine indications.
  • Biological E: Indian vaccine manufacturer with expansive pipeline including conjugate vaccines. Compares in product category (conjugate/bacterial vaccines), though larger scale and geographic focus differ.

Broad incumbents

  • GSK (Vaccines): Major global vaccine manufacturer with deep portfolio in bacterial and conjugate vaccines. Adjacent incumbent that has historically partnered with and acquired specialty vaccine biotechs of comparable size and platform type.
  • Sanofi Pasteur: Global vaccines division of Sanofi and one of the largest vaccine manufacturers. Broad incumbent with overlapping bacterial and conjugate vaccine programs; comparable as a potential partner/competitor in the same product class.
  • Merck & Co. (Vaccines): Leading pharmaceutical company with substantial infectious disease and bacterial vaccine franchises. Represents the scale boundary and potential acquirer profile of a successful smaller biotech platform player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

GlycoVaxyn social profiles

Digital presence

GlycoVaxyn financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GlycoVaxyn leadership team

Management profile

Number of profiles

Profiles1 record

GlycoVaxyn funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GlycoVaxyn M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlycoVaxyn

What does GlycoVaxyn do?

GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. Its core activity is vaccine research, development, and biological manufacturing of glycoconjugate candidates designed to prevent bacterial disease. The company operates as a small, private Swiss biopharmaceutical firm advancing its proprietary bioconjugate vaccine platform.

Is GlycoVaxyn a public or private company?

GlycoVaxyn is a private company. It is classified as venture growth investor backed and is currently operating.

When was GlycoVaxyn founded?

GlycoVaxyn was founded in 2004. It employs 11 to 50 people.

Where is GlycoVaxyn based?

GlycoVaxyn is headquartered in Schlieren, Switzerland, in the Europe region.

How does GlycoVaxyn make money?

One revenue line is on record: technology Infrastructure Services.

Who are GlycoVaxyn's main competitors?

Direct peers on record are Novavax, Bavarian Nordic, Emergent BioSolutions, Dynavax Technologies and Valneva. Emerging players are VBI Vaccines and Biological E. Broad incumbents are GSK (Vaccines), Sanofi Pasteur and Merck & Co. (Vaccines).

Does GlycoVaxyn have an API?

No public API is recorded for GlycoVaxyn.

What industry is GlycoVaxyn in?

GlycoVaxyn's product category is Biopharmaceutical vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAIAEAE, Travel & Tropical Disease Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales